Circulating Endothelial Cells in Neuroendocrine Tumors Abstract #757

Introduction: Circulating endothelial cells (CECs) are mature endothelial cells that are shed into the bloodstream. We hypothesised that neuroendocrine tumors (NETs), being highly vascular, may shed more CECs into the circulation, and that changes in their number may serve as a biomarker for anti-angiogenic therapy.
Aim(s): To compare the number of CECs in NET patients with that of healthy controls.
Materials and methods: Whole blood (4mls) was collected from healthy controls and patients with a diagnosis of metastatic NET. CECs were characterized morphologically and by the co-expression DAPI+CD105+CD45- and enumerated using the Cellsearch™ system. Intersample variability was assessed in a sub-group of controls and patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Dalvinder Mandair
Keywords: biomarker

To read results and conclusion, please login ...

Further abstracts you may be interested in

#722 Isolation and Whole Genome Amplification of Single Circulating Tumor Cells in Neuroendocrine Tumors: A Pilot Study
Introduction: We have previously demonstrated that Circulating Tumor Cells (CTCs) can be detected in patients with neuroendocrine tumors (NET) and that their presence is prognostic. Downstream analysis of CTCs provides an opportunity to explore their potential as biomarker for targeted therapy. Here we present initial data which demonstrates that molecular profiling can be successfully performed on single CTCs from patients with NETs
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Dalvinder Mandair
#491 International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR CHRISTOS Toumpanakis
#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)
Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Francesca Maria Rizzo
Keywords: CTC, CXCR4, bone
#1278 Midkine is a New Novel Serum Biomarker in Small Intestinal Neuroendocrine Tumors (SI-NETs).
Introduction: SI-NETs are often diagnosed late, which limits curative treatment options.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Kosmas Daskalakis
Keywords: Biomarker, SI-NET
#2083 Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study
Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Associate prof, Magnus Kjellman